TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›ANVS›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

Annovis Bio, Inc. (ANVS) financials

Income statement

Annovis Bio, Inc. (ANVS) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue—$0.00$0.00$0.00$0.00$0.00$0.00
Operating income-$1.61M-$6.64M-$14.5M-$25.5M-$45.0M-$26.7M-$29.7M
Net income-$991K-$5.46M-$14.5M-$25.3M-$56.2M-$24.6M-$28.9M
EPS (diluted)-$3.51-$0.87-$1.90-$3.10-$6.23-$2.31-$1.40

Cash flow

Annovis Bio, Inc. (ANVS) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$477K-$3.97M-$9.13M-$17.3M-$40.0M-$21.9M-$25.6M

Balance sheet

Annovis Bio, Inc. (ANVS) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$1.86K$8.07M$45.7M$28.4M$5.75M$10.6M$19.5M
Total assets$1.12M$8.12M$46.0M$36.0M$10.2M$13.9M$21.1M
Total liabilities$2.62M$578K$1.51M$7.70M$18.0M$4.62M$4.23M
Shareholders' equity-$8.58M$7.54M$44.5M$28.3M-$7.75M$9.31M$16.9M
Retained earnings-$8.78M-$14.2M-$28.7M-$54.1M-$110M-$135M-$164M
Shares (wtd avg diluted)283K6.31M7.63M8.16M9.02M12.2M20.6M

Every figure is extracted from Annovis Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Annovis Bio, Inc.'s annual revenue?
Annovis Bio, Inc. (ANVS) reported $0.00 of revenue for fiscal year 2025, per its annual report filed with the SEC.
Does ANVS pay a dividend?
Annovis Bio, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full ANVS analysis — verdict, score & filings →Is ANVS a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.